OneMedNet Corp 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a crossroads, attempting to trade a failing legacy product for a promising but capital-intensive data platform. While the growth in iRWD revenue is a strong signal of product-market fit, the financial statements highlight a desperate struggle for liquidity and operational stability. The massive reduction in liabilities through equity swaps has bought the company time, but it has also resulted in significant shareholder dilution. Ultimately, OneMedNet's survival depends on its ability to scale iRWD deliveries to the point where gross margins turn positive. Investors are weighing a high-upside bet on a regulatory-grade data moat against the very real possibility of insolvency or further dilution. The transition from a 'turnaround' story to a 'growth' story remains incomplete as long as the company relies on private placements and crypto volatility to fund its daily operations.